Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD Source: Eur Respir J 2011; 38: 797-803 Year: 2011
Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012
Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
A comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a double-blind, efficacy and safety study in Chinese adults with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006
Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009
48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study Source: Eur Respir J 2002; 20: 1138-1146 Year: 2002
Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009
A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Cardiac safety of indacaterol, a novel once-daily bronchodilator, in COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014
Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013